Jazz Pharmaceuticals Director Bruce Cozadd Sells $1.38M via Rule 10b5-1 Plan

Insider Transaction Overview

On October 1, 2026, Bruce C. Cozadd, a Director at Jazz Pharmaceuticals plc ($JAZZ), executed an open-market sale of 6,000 Ordinary Shares at a price of $230.33 per share. The transaction amounted to a total consideration of approximately $1,381,980.

Key Transaction Details

• Insider: Bruce C. Cozadd (Director)
• Filing Date: October 5, 2026
• Transaction Date: October 1, 2026
• Security: Ordinary Shares
• Transaction Code: S (Open-market sale)
• Shares Sold: 6,000
• Price Per Share: $230.33
• Total Transaction Value: $1,381,980.00
• Post-Transaction Holdings: 345,875 shares directly owned

Context & Trading Significance

1. Pre-Scheduled Plan: Footnote 1 explicitly indicates that the sale was conducted under a Rule 10b5-1 trading plan adopted on November 26, 2025. Rule 10b5-1 plans allow company insiders to schedule trades in advance when not in possession of material non-public information, avoiding discretionary timing.
2. Stake Reduction Size: Selling 6,000 shares against a remaining holding of 345,875 shares represents a reduction of approximately 1.7% of his direct equity stake. Cozadd continues to maintain a substantial ownership position in the company.
3. Market Significance Assessment: Given the adoption of a formal 10b5-1 trading plan nearly a year prior and the modest proportion of holdings sold, this transaction is assessed as having Low informational significance for the broader market.